Grifols, S.A. Stock Nasdaq

Equities

GRFS

US3984384087

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
6.48 USD +1.57% Intraday chart for Grifols, S.A. +2.86% -43.94%
Sales 2024 * 7.09B 7.6B Sales 2025 * 7.63B 8.18B Capitalization 5.1B 5.46B
Net income 2024 * 489M 524M Net income 2025 * 732M 784M EV / Sales 2024 * 2 x
Net Debt 2024 * 9.12B 9.77B Net Debt 2025 * 8.33B 8.93B EV / Sales 2025 * 1.76 x
P/E ratio 2024 *
10.8 x
P/E ratio 2025 *
7.59 x
Employees 23,744
Yield 2024 *
-
Yield 2025 *
2.83%
Free-Float 89.28%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.57%
1 week+2.86%
Current month-2.99%
1 month-2.99%
3 months-19.70%
6 months-17.35%
Current year-43.94%
More quotes
1 week
6.12
Extreme 6.12
6.52
1 month
6.12
Extreme 6.12
7.35
Current year
5.30
Extreme 5.3001
11.73
1 year
5.30
Extreme 5.3001
12.15
3 years
5.30
Extreme 5.3001
19.07
5 years
5.30
Extreme 5.3001
25.73
10 years
5.30
Extreme 5.3001
25.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 Feb. 05
Director of Finance/CFO 67 06-12-31
Chairman 65 06-04-04
Members of the board TitleAgeSince
Chairman 65 06-04-04
Director/Board Member 68 00-04-12
Director/Board Member 61 01-07-26
More insiders
Date Price Change Volume
24-04-29 6.48 +1.57% 1,106,086
24-04-26 6.38 +1.75% 673,447
24-04-25 6.27 -1.88% 1,012,213
24-04-24 6.39 -1.39% 963,534
24-04-23 6.48 +2.86% 3,409,923

Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT

More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
8.386 EUR
Average target price
18.03 EUR
Spread / Average Target
+115.03%
Consensus